PMV Pharmaceuticals, Inc. (PMVP)
Automate Your Wheel Strategy on PMVP
With Tiblio's Option Bot, you can configure your own wheel strategy including PMVP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PMVP
- Rev/Share 0.0
- Book/Share 2.7034
- PB 0.492
- Debt/Equity 0.0073
- CurrentRatio 12.5193
- ROIC -0.6296
- MktCap 70477849.0
- FreeCF/Share -1.3486
- PFCF -1.0048
- PE -0.8554
- Debt/Assets 0.0067
- DivYield 0
- ROE -0.4795
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Published: October 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial. Results were presented today in an oral presentation by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts. The ongoing Phase 1/2 PYNNACLE clinical trial is …
Read More
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
Read More
About PMV Pharmaceuticals, Inc. (PMVP)
- IPO Date 2020-09-25
- Website https://www.pmvpharma.com
- Industry Biotechnology
- CEO David H. Mack
- Employees 47